Multiple myeloma (MM) is a genetically complex disease that evolves from pre-malignant
stages, such as monoclonal gammaopathy of undetermined significance and smouldering …

B cell activation and differentiation yields plasma cells with high affinity antibodies to a given
antigen in a time-frame that allows for host protection. Although the end product is most …

Primary plasma cell leukemia (PCL) has a consistently ominous prognosis, even after
progress in the last decades. PCL deserves a prompt identification to start the most effective …

In multiple myeloma malignant plasma cells expand within the bone marrow. Since this site
is well-perfused, a rapid dissemination of “fitter” clones may be anticipated. However, an …

Extramedullary multiple myeloma (EMM) is an aggressive subentity of multiple myeloma,
characterized by the ability of a subclone to thrive and grow independent of the bone …

Multiple myeloma remains an incurable neoplasm of plasma cells that affects more than
20,000 people annually in the United States. There has been a veritable revolution in this …

Myeloma is a malignant proliferation of monoclonal plasma cells. Although morphologically
similar, several subtypes of the disease have been identified at the genetic and molecular …

Plasma cell leukemia (PCL) is a rare and aggressive variant of myeloma characterized by
the presence of circulating plasma cells. It is classified as either primary PCL occurring at …

The longitudinal evolution of a myeloma genome from diagnosis to plasma cell leukemia
has not previously been reported. We used whole-genome sequencing (WGS) on 4 purified …

Multiple myeloma is a monoclonal tumor of plasma cells, and its development is preceded
by a premalignant tumor with which it shares genetic abnormalities, including universal …